Work

Safety and clinical activity of anti-programmed death-ligand 1 (PD-L1) antibody (ab) avelumab (MSB0010718C) in advanced thymic epithelial tumors (TETs).

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.15_suppl.e20106

Authors: Arun Rajan, Christopher Ryan Heery, Susan Perry, Corrine Keen, Andrew L Mammen, Arlene W. Berman, Stefania Pittaluga, Lauren Marissa Lepone, Renee Nicole Donahue, Italia Grenga, Jeffrey Schlom, Raffit Hassan, James L. Gulley

Institutions: National Institutes of Health, National Cancer Institute, Center for Cancer Research, National Institute of Arthritis and Musculoskeletal and Skin Diseases

Language: English

Topic: Myasthenia Gravis and Thymoma

Subfield: Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2889614152

Cites:

Cited by: 11

Related to: 10